Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A gene therapy targeting PCSK9 achieved sustained LDL cholesterol reduction in early trials, suggesting a potentially durable approach to cardiovascular risk reduction beyond conventional statin therapy. The durability of genetic intervention raises questions about how to integrate such tools within comprehensive cardiovascular prevention strategies.
A neuron-specific protein disposal mechanism called the membranal proteasome has been identified as a key player in tau aggregation and Alzheimer's pathology. This finding reframes neurodegeneration not as a mutation problem but as a failure in cellular quality control, with direct implications for how protein misfolding accumulates in the aging brain.
Environmental chemical exposures—the exposome—now explain mortality variation better than genetics, yet remain largely unmeasured in population health studies. Systematic quantification of synthetic chemicals in biobank samples could identify disease drivers and inform large-scale risk reduction.
Alnylam and Inceptive have partnered to use generative AI models to accelerate RNA interference drug design, leveraging two decades of proprietary siRNA data and six approved therapeutics. This collaboration demonstrates how machine learning can compress drug development timelines by identifying optimal molecular candidates from biological datasets, with potential applications across multiple therapeutic areas.
Leica Biosystems, AstraZeneca, and Daiichi Sankyo have expanded their collaboration to develop an AI-powered algorithm for detecting TROP2 biomarker expression in lung cancer tissue samples. This integration of immunohistochemistry assay development with computational pathology creates a standardized approach to identifying patients who may benefit from targeted therapies, advancing precision oncology methods.
Magnesium functions as a central regulator of mitochondrial ATP production and metabolic resilience, with age-related declines in cellular magnesium contributing to insulin resistance, metabolic inflexibility, and accelerated aging. This positions magnesium homeostasis as a mechanistic checkpoint linking energy production capacity to disease risk and longevity.
Aged skeletal muscle exhibits an exaggerated mitochondrial unfolded protein response to physical stress, driven by reduced protein-folding capacity and elevated reactive oxygen species signaling. This amplified stress response reflects compromised mitochondrial resilience and suggests potential targets for preserving muscle function during aging.
Axo Longevity will present a data-driven preventive health platform at The Longevity Show 2026 that combines comprehensive biomarker testing, wearable metrics, and AI-powered interpretation to identify physiological changes before they become clinical problems. This represents a shift in longevity medicine from reactive treatment toward continuous monitoring and early signal detection.
Montara Therapeutics is developing a brain-selective approach to mTOR inhibition that targets alpha-synuclein accumulation in Parkinson's disease while avoiding systemic side effects. The strategy uses a proprietary peripheral blocker to confine therapeutic activity to the central nervous system, addressing a longstanding limitation that has prevented effective translation of mTOR-targeting compounds into neurological treatments.
Fresenius Medical Care launched Kinexus Worldwide, a digital platform enabling remote monitoring, prescription management, and supply ordering for home dialysis patients. The system transmits treatment data to clinics in real time, allowing clinicians to adjust therapy protocols without requiring in-person visits.
Methylglyoxal, a byproduct of glucose metabolism, accelerates kidney filtration decline through mechanisms that mirror aging itself. This identifies a modifiable metabolic driver of progressive kidney dysfunction, a hallmark of age-related decline affecting multiple organ systems.
Cancer burden in adults aged 65+ across Asia increased substantially from 1990 to 2023, with patterns reflecting aging populations and shifting risk factor prevalence. This trajectory reflects decades of cumulative exposure to modifiable and non-modifiable factors, making prevention and early detection critical to extending healthspan in rapidly aging Asian populations.